Ani Pharmaceuticals Inc
ANIP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001023024
In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 11 sales; 290 institutions reported holding it in 13F filings for Q3 2026, worth $1.66B in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.36M in total
- 11
- 13F holdersQ3 2026, −11 vs. previous quarter
- 290
- 13F valueReported value at the end of Q3 2026
- $1.66B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $883.4M
- +43.8% year over year
- Net income, FY2025
- $78.3M
- No comparable prior period
- Free cash flow, FY2025
- $171.4M
- +258.7% year over year
- Revenue, Q3 FY2026
- $290.8M
- +27.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.58M
- Shares sold short
- Change
- +111.6K
- +3.2% vs. previous
- Days to cover
- 11.88
- At average daily volume
Superinvestors holding ANIP, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding ANIP at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Ani Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)8:32 PM ET | Nov 16-18 | 2 days | Lalwani NikhilPRESIDENT & CEO | SSale | −5.40K | $71.22 | −$384.6K | −1.6%328.3K after | 2 lots10b5-1 |
| Nov 13, 2026 (view filing)4:35 PM ET | Nov 13 | Same day | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | SSale | −500 | $70.80 | −$35.4K | −0.7%72.9K after | 10b5-1 |
| Oct 30, 2026 (view filing)4:36 PM ET | Oct 29 | 1 day | Carey Stephen P.SVP & CFO | SSale | −2.85K | $72.87 | −$207.7K | −1.7%166.1K after | 10b5-1 |
| Oct 16, 2026 (view filing)6:50 PM ET | Oct 15 | 1 day | Lalwani NikhilPRESIDENT & CEO | SSale | −5.40K | $71.89 | −$388.2K | −1.6%333.7K after | 10b5-1 |
| Oct 13, 2026 (view filing)8:47 PM ET | Oct 13 | Same day | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | SSale | −500 | $73.59 | −$36.8K | −0.7%73.4K after | 10b5-1 |
| Sep 30, 2026 (view filing)4:52 PM ET | Sep 29 | 1 day | Carey Stephen P.SVP & CFO | SSale | −2.85K | $73.00 | −$208.1K | −1.7%169.0K after | 10b5-1 |
| Sep 16, 2026 (view filing)4:20 PM ET | Sep 15 | 1 day | Lalwani NikhilPRESIDENT & CEO | SSale | −5.40K | $71.00 | −$383.4K | −1.6%339.1K after | 10b5-1 |
| Sep 14, 2026 (view filing)8:57 PM ET | Sep 11 | 3 days | Thoma JeanneDirector | SSale | −1.00K | $71.53 | −$71.5K | −3.6%26.8K after | 10b5-1 |
| Sep 14, 2026 (view filing)8:56 PM ET | Sep 14 | Same day | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | SSale | −500 | $70.79 | −$35.4K | −0.7%73.9K after | 10b5-1 |
| Sep 1, 2026 (view filing)6:18 PM ET | Aug 31 | 1 day | Carey Stephen P.SVP & CFO | SSale | −2.85K | $72.80 | −$207.5K | −1.6%171.8K after | 10b5-1 |
Top 10 13F holders, Q3 2026
See all 290 holdersThe largest institutional positions in Ani Pharmaceuticals Inc at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,155,865 | $229.3M | 0.00% | +197,219+6.7% | Added |
| Soleus Capital Management, L.P. | 975,500 | $70.9M | 2.52% | +107,740+12.4% | Added |
| State Street Corp | 950,970 | $69.1M | 0.00% | +119,323+14.3% | Added |
| American Century Companies Inc | 912,647 | $66.3M | 0.03% | +338,173+58.9% | Added |
| Vanguard Capital Management LLC | 904,707 | $65.7M | 0.00% | +66,483+7.9% | Added |
| Dimensional Fund Advisors LP | 728,748 | $52.9M | 0.01% | +105,285+16.9% | Added |
| Tang Capital Management LLC | 707,500 | $51.4M | 2.36% | 00.0% | Unchanged |
| UBS Group AG | 621,335 | $45.1M | 0.01% | +323,796+108.8% | Added |
| Geode Capital Management, LLC | 545,063 | $39.6M | 0.00% | +8,656+1.6% | Added |
| Deep Track Capital, LP | 500,000 | $36.3M | 0.61% | +500,000 | New |
Holders of 5% or more of ANIP
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Ani Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 12.80%2.90M shares | +1.50 ppfrom 11.30% | Oct 17, 20252 filings | Jul 27, 2026 | SEC |